Essential considerations when choosing a modern antidepressant

International Journal of Psychiatry in Clinical Practice

Volumn 7, Issue SUPPL. 1, 2003, Pages 3-8

  Baldwin, David ^a  

^a NONE

Author keywords

Antidepressant; Choice; Criteria; Noradrenaline; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LOFEPRAMINE; MELATONIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; PAROXETINE; PROPRANOLOL; PROTON PUMP INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANXIETY DISORDER; COGNITIVE DEFECT; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DYSURIA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PANIC; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEDATION; SEXUAL DYSFUNCTION; SOMNOLENCE; SWEATING; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0043270297     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500310000825     Document Type: Conference Paper

References (26)

1. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509-22.
2. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM (1992) Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DM1 in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 43: 65-76.
3. Richelson E (1994) Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clinic Proc 69: 1069-81.
4. Potter WZ, Manji HK (1994) Catecholamines in depression: an update. Clin Chem 40: 279-87.
5. Sitsen JMA, Zivkov M (1995) Mirtazapine: clinical profile. CNS Drugs 4 (Suppl 1): 39-48.
6. Holm KJ, Markham A (1999) Mirtazapine: a review of its use in major depression. Drugs 57: 607-31.
7. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303-7.
8. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K (1992) Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161: 562-5.
9. Baldwin D, Thompson C (2003) The future of antidepressant pharmacotherapy World Psychiatry (in press).
10. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238-49.
11. Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl 1): 11-7.
12. Anderson IM, Nutt DJ, Deakin JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology J Psychopharmacol 14: 3-20.
13. Sechter D, Weiller E, Pezous N, Bisserbe JC (2003) Psychomotor retardation as a predictive factor favouring a positive clinical response to milnacipran. Int Clin Psychopharmacol (in press).
14. Clerc G, the Milnacipran/Fluvoxamine Study group (2001) Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 16: 145-51.
15. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR (1999) Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom. J Psychopharmacol 13: 136-43.
16. Puech A, Montgomery SA, Prost JF, Solles A, Briley M (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
17. Fukuchi T, Kanemoto K (2002) Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol 17: 53-8.
18. Stanton LA, Peterson GM, Rumble RH, Cooper GM, Polack AE (1994) Drug-related admissions to an Australian hospital. J Clin Pharm Ther 19: 341-7.
19. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. J Am Med Assoc 277: 301-6.
20. Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153: 311-20.
21. Puozzo C, Leonard BE (1996) Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4): 15-27.
22. Briley M, Moret C (1997) Antidepressant properties of specific serotonin-noradrenaline reuptake inhibitors. In: Skolnick P (ed.) Antidepressants: New Pharmacological Strategies. Totowa, NJ: Humana Press: 35-52.
23. Sawada Y, Ohtani H (2001) Pharmacokinetics and drug interactions of antidepressive agents. Nippon Rinsho 59: 1539-45.
24. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B (2002) Discontinuation of use and switching of antidepressants: influence of patient-physician communication. J Am Med Assoc 288: 1403-9.
25. Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4): 35-9.
26. Henry JA, Alexander CA, Sener EK (1995) Relative mortality from overdose of antidepressants. Br Med J 310: 221-4.